Replies to post #280896 on Avid Bioservices Inc (CDMO)

[cheynew]

Don't you think it is weird that the PR yesterday (below) is not on either Peregrine's or Avid's websites? Also, I am signed up to get emails on PRs but got nothing. Anyone else?

December 9, 2016 8:05 AM
Avid Bioservices to Participate at Upcoming Life Sciences Industry Conferences

TUSTIN, CA--(Marketwired - Dec 9, 2016) - Avid Bioservices, Inc., a wholly owned subsidiary of Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced that the company will attend and participate at two upcoming life sciences industry conferences. The company will host a corporate booth in the exhibit hall at KNect365 Life Sciences' Antibody Engineering & Therapeutics conference. In addition, Pete Gagnon, Avid's vice president, process sciences, will present a case study on innovative applications for antibody manufacturing processes at the 16th Annual Global Bioproduction Summit.

Details of these activities are as follows:

KNect365 Life Sciences' Antibody Engineering & Therapeutics: December 11-15, 2016, San Diego, CA

Avid will host corporate booth #209 showcasing the company's comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. These include a variety of innovative processes for generating a broad range of biopharmaceutical product types such as monoclonal antibodies, highly-glycosylated recombinant proteins and enzymes, among others. These capabilities also extend to the manufacture of biosimilar products and are designed to support the overall ongoing growth of the company's contract manufacturing business.

16th Annual Global Bioproduction Summit: December 12-13, 2016, San Diego, CA

Mr. Gagnon will present a case study highlighting the importance of managing keystone contaminants in downstream processing. The presentation, which will take place from 10:55 - 11:25 a.m. (Pacific) on Monday, December 12th, will detail streamlined manufacturing processes for removing chromatin from cell culture harvests to enable improved purification process economics and product quality. The content of this case study showcases the industry-leading manufacturing expertise that Avid offers to its clients.

For additional details on these events, please visit: https://lifesciences.knect365.com/antibody-engineering-therapeutics/ and http://www.biologicalproduction.com/.

About Avid Bioservices
Avid Bioservices provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With over 15 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. For more information about Avid, please visit www.avidbio.com.

About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of patients by delivering high quality pharmaceutical products through its contract development and manufacturing organization (CDMO) services and through advancing and licensing its investigational immunotherapy and related products. Peregrine's in-house CDMO services, including cGMP manufacturing and development capabilities, are provided through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. The company is also working to evaluate its lead immunotherapy candidate, bavituximab, in combination with immune stimulating therapies for the treatment of various cancers, and developing its proprietary exosome technology for the detection and monitoring of cancer. For more information, please visit www.peregrineinc.com.

Contacts:
Kelly Pisarev Lord
Avid Bioservices, Inc.
[phone]

Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
Email Contact

Tim Brons (Media)
Vida Strategic Partners
415-675-7402
Email Contact


News Provided by QuoteMedia.

[Dragon Lady]

Quote LOL, "Bungler, I opened a chart of PPHM daily bars and look over the past 24 months (that is 8 quaraters) and I could not find a pattern in the large volume days with a PPS lift. "

Better CHECK THAT CHART AGAIN, LOL !!

The 2nd volume "bar" after June 1st, 2016 is at 15 MILLION SHARES TRADED, the stock went in a single line UP from around 40 CENTS a share greater than 50 CENTS a share (uh...checking...that's a greater than 20% SINGLE MOVE, ON HUGE VOLUME, really a 25% move, bigger than yesterdays) w/ a daily price "spike" (see vertical black "share price" line on the chart, above the same volume bar) that nearly touched 70 CENTS a share.

Early June was a series of SEC filed 8-K releases w/ PR pumps put out to coincide with them, about the "big new biz plans" and "highlighting contract manufacturing developments" a blah blah, and some other "stuff".

The common shares then went on to GIVE BACK ALL THOSE GAINS in the rest of the month of JUNE, breaking a tad back under 40 CENTS a share, but then spending a decent part of July trading ABOVE 40 CENTS A SHARE, meaning WELL ABOVE WHERE THEY ARE RIGHT NOW....and it didn't amount to jack crap, nor did it ever come close to lifting the stock out of the REVERSE SPLIT ZONE, where it is SOLIDLY PARKED TO THIS DAY, nearly 6 MONTHS LATER.

Simple as that.



THERE IT IS, PLAIN AS DAY....the "big start of June move"...and...and...and it ultimately amounted to NOTHING, and it was a single move UP on almost 50% more VOLUME than the move up yesterday....AND notice again, that in July, the shares spent most of that month trading ABOVE WHERE THEY ARE RIGHT NOW...and they never went anywhere near the levels needed to prevent a REVERSE SPLIT or else face a NASDAQ DE-LISTING....yepper...right there on the ole chart...CLEAR AS DAY TO ME....

Oh and one can also look at things like:

10-K RELEASED on July 7, 2016 and shares move from maybe 35 cents ea, all the way up to 45 CENTS each, in the period leading up to the LOSS REPORT.

Or, March 9th, 10-Q released, and shares make MEGA MOVE from below 34 CENTS EACH, spiking on high volume to approx as high as 60 CENTS EACH, only to dump-off, and give it ALL BACK post the quarterly LOSS REPORT. (A PATTERN FORMING....uh oh....shares get pumped up heading into quarterly LOSS REPORTS....)

Or, 9-8-2016 10-Q quarterly LOSS REPORT, the shares begin at "maybe" 36 CENTS or so, then make a fairly large move UP, reaching ABOVE 50 CENTS A SHARE in the period directly leading into the LOSS REPORT, and for a few weeks after, THEN COLLAPSE AND GIVE IT ALL BACK....CLEARLY seen on the chart above, yepper....looks like a pattern to me....3 makes a pattern IMO....and it's right there on the chart.....

[asmarterwookie]

Never this much volume or percentage rise before a quarterly. Maybe Dr. Wolchok decided to put some order to the immunostimulatory chaos and even get a little chaotic with the BPs who like everything in their own basket.

I was rushed and excited...great word CP! ; )

wook